Preclinical CRO Market Report 2026

Preclinical CRO Market Overview

• Preclinical CRO market size has reached to $6.25 billion in 2025 • Expected to grow to $9.83 billion in 2030 at a compound annual growth rate (CAGR) of 9.5% • Growth Driver: Surging Demand For Preclinical Trials Drives Growth In The Preclinical CRO Market • Market Trend: Revolutionizing Preclinical Drug Discovery • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

The key promising market opportunities in the preclinical cro services market include: • Small Animal Model (Segmentation By Animal Model) → Expected gain of $2817.66 Million • Oncology (Segmentation By Disease Area) → Expected gain of $1402.53 Million • Toxicology and Safety Assessment (Segmentation By Service Type) → Expected gain of $1139.79 Million

What Is Covered Under Preclinical CRO Market?

Preclinical CROs (contract research organizations) are support organizations that provide the knowledge in research and development needed to guide a drug candidate through animal testing and advance it to the clinical stage. A preclinical CRO supports new medical product producers in showing product safety and efficacy in living animals that the Food and Drug Administration (FDA) considers mirroring human anatomy most closely before entering clinical trials or being used for human care. The main services of preclinical CRO are bioanalysis and DMPK studies, toxicology testing, compound management, chemistry, safety pharmacology, and others. A small three-dimensional (3D) cell culture made from a patient's cancer cells is known as a patient-derived organoid (PDO), and it has undergone substantial investment and experimental validation to offer prospective therapeutic alternatives for the diagnosis of complex diseases. The various types of preclinical CRO including the patient-derived organoid (PDO) model and the patient-derived xenograft model are available for small animal and large animal models. The model systems In Vivo and In Vitro are used by biopharmaceutical companies, government and academic institutes, medical device companies, and others.

What Is The Preclinical CRO Market Growth Forecast?

The preclinical cro market size is expected to see strong growth in the next few years. It will grow to $9.83 billion in 2030 at a compound annual growth rate (CAGR) of 9.5%. The growth in the forecast period can be attributed to increasing demand for precision medicine research, rising focus on rare disease drug development, expansion of biologics and cell therapy pipelines, growing adoption of digital preclinical platforms, increasing partnerships between pharma companies and CROs. Major trends in the forecast period include increasing adoption of integrated preclinical study services, rising demand for advanced animal model expertise, growing outsourcing of early-stage drug development, expansion of regulatory-aligned toxicology capabilities, enhanced focus on data-driven study design.

What Is The Driver Of The Preclinical CRO Market?

The increasing demand for preclinical trials is expected to propel the growth of the preclinical CRO market going forward. Preclinical trials refer to any study conducted on medicine or treatment for a condition before human volunteers are used as test subjects. Preclinical studies often involve novel medical devices, prescription medications, and diagnostics, and its primary objectives are to establish a beginning, safe dose for first-in-human research and evaluate any potential toxicity of the product. Preclinical trials play a critical role in drug development, and their importance is increasing with the growing emphasis on the safety and efficacy of new drugs. For instance, in February 2024, according to IQVIA, a US-based company serving the combined industries of health information technology and clinical research reports, clinical development productivity rose in 2023, where a total of 69 novel active substances (NASs) were launched globally in 2023, 6 more than the prior year, and including 24 first-in-class launches in the U.S. Therefore, the increasing demand for preclinical trials is driving the growth of the preclinical CRO industry going forward.

How Will The Drivers Impact Growth In The Global Preclinical CRO Services Market?

• Expansion Of Biologics, Cell & Gene Therapy Pipelines (High) – During forecast period, expansion of biologics, cell & gene therapy pipelines is expected to propel the growth of the preclinical CRO services market. These advanced therapies involve complex biological mechanisms and require specialized preclinical studies, including safety, efficacy, toxicology and bioanalytical testing. Many biopharmaceutical companies lack in-house capabilities to manage these sophisticated requirements, increasing their reliance on experienced CROs. Additionally, the rising number of early-stage biotech firms developing innovative modalities is boosting demand for outsourced pre-clinical expertise. CROs that offer advanced models, regulatory support and integrated services are well positioned to benefit from this growing demand. Therefore, expansion of biologics, cell & gene therapy pipelines will drive the growth of the preclinical CRO services market. The expansion of biologics, cell & gene therapy pipelines during the forecast period in 2025 is 2.0%. • Growing Number Of Drug Candidates Requiring IND-Enabling Studies (Medium) – During the forecast period, the growing number of drug candidates requiring ind-enabling studies is expected to propel the growth of the preclinical cro services market during forecast period. before filing an investigational new drug (ind) application, sponsors must complete comprehensive ind-enabling studies, including pharmacology, toxicology, pharmacokinetics and safety assessments. as drug pipelines expand across small molecules and complex biologics, the volume and complexity of these studies continue to rise. many pharmaceutical and biotechnology companies choose to outsource these activities to specialized cros to reduce development timelines, manage costs and access regulatory expertise. this growing reliance on outsourced ind-enabling services is a key driver supporting sustained market growth. therefore, the growing number of drug candidates requiring ind-enabling studies will drive the growth of the preclinical cro services market. the growing number of drug candidates requiring ind-enabling studies during the forecast period in 2025 is 1.5%. • Growing Demand To Accelerate Time-To-Clinic And First-In-Human Studies (Medium) – During forecast period, the growing demand to accelerate time-to-clinic and first-in-human studies is expected to propel the growth of the preclinical CRO services market. Pharmaceutical and biotechnology companies are under increasing pressure to shorten development timelines and gain early clinical proof of concept to remain competitive. Preclinical CROs help achieve this by offering streamlined study designs, advanced models and integrated regulatory support that enable faster data generation for IND submissions. Outsourcing preclinical activities also allows sponsors to avoid infrastructure investments and scale resources efficiently. As speed to clinical milestones becomes a strategic priority, reliance on specialized CRO partners is expected to increase steadily. Therefore, the growing demand to accelerate time-to-clinic and first-in-human studies will drive the growth of the preclinical CRO services market. The growing demand to accelerate time-to-clinic and first-in-human studies during the forecast period in 2025 is 1.0%. • Growing Reliance On Contract Research Organizations (Low) – During the forecast period, the growing reliance on contract research organizations is expected to propel the growth of the preclinical cro services market during forecast period. pharmaceutical and biotechnology companies are increasingly outsourcing preclinical activities to cros to improve operational efficiency, control costs and access specialized scientific expertise. cros offer advanced infrastructure, experienced personnel and regulatory knowledge that many sponsors lack internally. this outsourcing approach also provides flexibility to scale resources based on project needs and reduces the risks associated with maintaining in-house capabilities. as drug development pipelines expand and preclinical requirements become more complex, dependence on cro partners is expected to increase, supporting sustained market growth. therefore, the growing reliance on contract research organizations will drive the growth of the preclinical cro services market. the growing reliance on contract research organizations during the forecast period in 2025 is 0.5%.

How Will The Restraints Impact Growth In The Global Preclinical CRO Services Market?

• Regulatory Uncertainty And Evolving Global Compliance Standards (High) – During the forecast period, regulatory uncertainty and evolving global compliance standards are expected to hinder the growth of the preclinical cro services market in forecast period. differences in regulatory requirements across regions, along with frequent updates to safety, data integrity and animal welfare guidelines, increase operational complexity for cros. ensuring compliance with multiple regulatory frameworks requires continuous investment in quality systems, trained personnel and documentation processes, which can raise costs and extend study timelines. for sponsors, uncertainty around regulatory expectations may delay outsourcing decisions or project initiation. these challenges can reduce efficiency and slow preclinical progress, thereby restraining overall market growth despite rising demand for outsourced research services. therefore, regulatory uncertainty and evolving global compliance standards may hinder the growth of the preclinical cro services market. growth affected by regulatory uncertainty and evolving global compliance standards during the forecast period in 2025 is -2.5%. • Capacity Constraints And Skilled Workforce Shortages (Medium) – During the forecast period, capacity constraints and skilled workforce shortages are expected to hinder the growth of the preclinical CRO services market. Rising demand for outsourced preclinical studies has increased pressure on CRO infrastructure, laboratory capacity and specialized resources. At the same time, there is a limited supply of experienced scientists, toxicologists and regulatory professionals with expertise in advanced modalities. These shortages can lead to longer project timelines, higher service costs and reduced flexibility in handling multiple programs simultaneously. As a result, CROs may struggle to meet client expectations for speed and scalability, which could limit market expansion despite strong underlying demand. Therefore, capacity constraints and skilled workforce shortages at CROs may hinder the growth of the preclinical CRO services market. Growth affected by capacity constraints and skilled workforce shortages during the forecast period in 2025 is -1.5%. • Trade War And Tariffs (Medium) – During the forecast period, trade wars and tariffs are expected to restrain the growth of the preclinical cro services market during the forecast period, as higher duties on imported laboratory reagents, research consumables, animal models and specialized equipment increase operational and procurement costs for cros. increasing duties on imported laboratory reagents, research consumables, animal models and specialized analytical equipment raise operational and procurement costs for cros. these higher input costs can compress margins or be passed on to pharmaceutical and biotechnology clients, potentially reducing outsourcing demand. in addition, trade restrictions may disrupt global supply chains, leading to delays in study execution and longer project timelines. uncertainty around cross-border trade policies can also discourage international collaborations and investments, limiting market expansion despite strong demand for pre-clinical research services. therefore, trade wars and tariffs may restrain the growth of the preclinical cro services market. growth affected by trade wars and tariffs during the forecast period in 2025 is -0.3%.

Key Players In The Global Preclinical CRO Market

Major companies operating in the preclinical cro market are Eurofins Scientific SE, WuXi AppTec Co Ltd, Medpace Holdings Inc, Charles River Laboratories International Inc, Laboratory Corporation Of America Holdings, Intertek Group plc, Crown Bioscience International, Cynbiose, AmplifyBio LLC, Vivotecnia SL, Altasciences Company Inc, Pharmaceutical Product Development LLC, Parexel International Corporation, Envigo RMS Holding Corporation, Veeda Clinical Research Ltd, ICON plc, Kunming Biomed International Ltd, PharmaLegacy Laboratories, NorthEast BioAnalytical Laboratories LLC, MDS Pharma Services, MPI Research, Toxikon Corporation, BioReliance Corporation, Covance Inc, Syngene International Limited

Global Preclinical CRO Market Trends and Insights

Major companies operating in the preclinical CRO market are adopting new technologies to sustain their position such as a disease biology knowledge graph to enhance target identification and drug discovery in pharmaceutical research. The disease biology knowledge graph is a structured, comprehensive representation of the relationships between genes, proteins, pathways, and disease phenotypes, designed to integrate diverse biological data. It enables researchers to systematically explore disease mechanisms, identify potential therapeutic targets, and accelerate drug discovery by providing a holistic map of disease biology. For instance, in February 2023, BenchSci, a Canada-based AI solutions company for preclinical R&D, launched ASCEND, an end-to-end SaaS (software as a service) platform and for preclinical drug discovery. By gaining biological insights into the fundamental underpinnings of disease, this method seeks to speed up preclinical phase drug development pipelines. ASCEND extracts experimental data from safe internal and public external sources using BenchSci's machine-learning technology. The platform compares experimental results using curated ontology datasets. As a result, the software can produce a map of the biological processes underpinning various diseases that are based on evidence.

What Are Latest Mergers And Acquisitions In The Preclinical CRO Market?

In September 2024, PharmaLegacy Laboratories, a US-based preclinical drug development CRO, acquired BTS Research for an undisclosed amount. Through this acquisition, PharmaLegacy aims to expand its in vitro and in vivo preclinical services, increase study capacity across North America, and strengthen its global service offerings. BTS Research is a US-based preclinical CRO providing GLP and non-GLP biological services to pharmaceutical, biotech, medical-device, and diagnostic clients.

What Defines the Preclinical CRO Market?

The preclinical CRO market includes revenues earned by entities through project management, information gathering, medical evaluations, maximum dose research, adherence to regulations, efficacy and safety reporting, and quality analysis. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Preclinical CRO Market Report 2026?

The preclinical cro market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the preclinical cro industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.